ÃÀ¸ß÷
ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞЧÀÍ×Éѯ£¬£¬£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com




1. 8ÔÂ16ÈÕ£¬£¬£¬£¬£¬ÈýÉú¹ú½¡ÖØ×éBDCA2¿¹ÌåµÄÁÙ´²ÊÔÑéÉêÇë»ñµÃNMPAÊÜÀí£¬£¬£¬£¬£¬ÕâÒ²ÊÇÊ׿î¹ú²úBDCA2¿¹Ìå¡£¡£¡£BiogenµÄBIIB059ΪȫÇòÊ׿îBDCA2¿¹Ì壬£¬£¬£¬£¬ÓÃÓÚÖÎÁÆÏµÍ³ÐÔºì°ßÀÇ´¯£¬£¬£¬£¬£¬ÏÖÔÚ´¦ÓÚÈýÆÚÁÙ´²½×¶Î¡£¡£¡£
2. 8ÔÂ16ÈÕ£¬£¬£¬£¬£¬·²¶÷ÊÀÖÆÒ©¹«Ë¾£¨Phanes Therapeutics£©Ðû²¼£¬£¬£¬£¬£¬ÃÀ¹úʳÎïÒ©Æ·¼àÊÓ¹ÜÀí¾Ö£¨FDA£©ÊÚÓèÆäPT217¹Â¶ùÒ©È϶¨£¬£¬£¬£¬£¬ÓÃÓÚÖÎÁÆÉñ¾ÄÚÉøÍ¸°©£¨NEC£©¡£¡£¡£
3. 8ÔÂ16ÈÕ£¬£¬£¬£¬£¬CDE¹ÙÍø¹«Ê¾£¬£¬£¬£¬£¬°¢Ë¹Àû¿µ£¨AstraZeneca£©ÖذõPD-L1ÒÖÖÆ¼Á¶È·¥ÀûÓȵ¥¿¹×¢ÉäÒºÐÂ˳Ӧ֢ÉÏÊÐÉêÇë»ñµÃÊÜÀí£¬£¬£¬£¬£¬Ïêϸ˳Ӧ֢ÉÐÎÞÅû¶¡£¡£¡£¶È·¥ÀûÓȵ¥¿¹£¨durvalumab£©´ËǰÒѾÔÚÖйú»ñÅúÖÎÁÆ·ÇСϸ°û·Î°©¡¢ÆÕ±éÆÚСϸ°û·Î°©¡¢µ¨µÀ°©Ë³Ó¦Ö¢¡£¡£¡£
4. 8ÔÂ16ÈÕ£¬£¬£¬£¬£¬CDE¹ÙÍø¹«Ê¾£¬£¬£¬£¬£¬»ÔÈð£¨Pfizer £©É걨µÄ°¢ÎôÌæÄáÆ¬ÐÂ˳Ӧ֢ÉÏÊÐÉêÇë»ñµÃÊÜÀí£¬£¬£¬£¬£¬Ïêϸ˳Ӧ֢ÉÐÎÞÅû¶¡£¡£¡£°¢ÎôÌæÄᣨaxitinib£©ÊÇÒ»¿îÄܹ»ÒÖÖÆVEGFR1-3»îÐÔµÄÀÒ°±ËἤøÒÖÖÆ¼Á£¨TKI£©£¬£¬£¬£¬£¬´ËǰÒÑÔÚÖйú»ñÅúÓÃÓÚÖÎÁÆÉöϸ°û°©¡£¡£¡£
1. 8ÔÂ14ÈÕ£¬£¬£¬£¬£¬»ª¶«Ò½Ò©Ðû²¼£¬£¬£¬£¬£¬È«×Ê×Ó¹«Ë¾º¼ÖÝÖÐÃÀ»ª¶«ÖÆÒ©ÓÐÏÞ¹«Ë¾Ó뺫¹úIMBiologicscorp.Ç©ÊðÁ˲úÆ·¶À¼ÒÔÊÐíÐÒé¡£¡£¡£ÖÐÃÀ»ª¶«»ñµÃIMBÁ½¿î×ÔÉíÃâÒßÁìÓòµÄÈ«ÇòÁ¢Òì²úÆ·IMB-101¼°IMB-102ÔÚ°üÀ¨ÖйúÔÚÄÚµÄ37¸öÑÇÖÞ¹ú¼Ò£¨²»º¬ÈÕ±¾£¬£¬£¬£¬£¬º«¹úºÍ³¯ÏÊ£©µÄ¶À¼ÒÔÊÐí£¬£¬£¬£¬£¬°üÀ¨¿ª·¢¡¢×¢²á¡¢Éú²ú¼°ÉÌÒµ»¯È¨Òæ¡£¡£¡£ÖÐÃÀ»ª¶«½«ÏòIMBÖ§¸¶600ÍòÃÀÔªÊ׸¶¿î£¬£¬£¬£¬£¬200ÍòÃÀÔª¼¼Êõ×ªÒÆÀï³Ì±®¸¶¿î£¬£¬£¬£¬£¬×î¸ß²»Áè¼Ý3.075ÒÚÃÀÔªµÄ¿ª·¢¡¢×¢²á¼°ÏúÊÛÀï³Ì±®¸¶¿î£¬£¬£¬£¬£¬ÒÔ¼°·Ö¼¶×î¸ßÁ½Î»ÊýµÄ¾»ÏúÊÛ¶îÌá³É·Ñ¡£¡£¡£
1. 8ÔÂ14ÈÕ£¬£¬£¬£¬£¬Ìì½òÒ½¿Æ´óѧ»ù´¡Ò½Ñ§ÔºÉú»¯Ïµ¡¢Ìì½òÊÐÃâÒßѧÑо¿ËùÕźãÍŶÓÁªºÏÖйú¿ÆÑ§ÔºÎ人²¡¶¾ËùµËÔöÇÕÍŶӣ¬£¬£¬£¬£¬ÔÚ Nature ½ÒÏþÑо¿¡£¡£¡£Ì½ÌÖÁË VII ÐÍ CRISPR-Cas ¼¶Áª¸´ºÏÌåµÄÀä¶³µç¾µ½á¹¹£¬£¬£¬£¬£¬·¢Ã÷ Cas14 ÔÚÈÜÒºÖÐÊÇÒ»¸öËľÛÌåÂѰף¬£¬£¬£¬£¬ÒÔ°Ð RNA ÒÀÀµµÄ·½·¨±»ÕÐļµ½ Cas5-Cas7 ¸´ºÏÌåÖС£¡£¡£
[1] Yang, J., Li, X., He, Q. et al. Structural basis for the activity of the type VII CRISPR¨CCas system. Nature (2024). https://doi.org/10.1038/s41586-024-07815-0
Ïà¹ØÐÂÎÅ